Nymalize is owned by Azurity.
Nymalize contains Nimodipine.
Nymalize has a total of 7 drug patents out of which 0 drug patents have expired.
Nymalize was authorised for market use on 10 May, 2013.
Nymalize is available in solution;oral dosage forms.
Nymalize can be used as a method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms.
The generics of Nymalize are possible to be released after 16 April, 2038.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7070581 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
Jun, 2023
(14 days from now) | |
US8517997 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(11 months from now) | |
US10576070 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
US11207306 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
US10342787 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
US11413277 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
US11517563 | AZURITY | NA |
Apr, 2038
(14 years from now) |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...
Dosage: SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic